Gastrosafety of rheumatoid arthritis pharmacotherapy

Aim. Analysis of gastroenterological adverse events of rheumatoid arthritis (RA) pharmacotherapy and measures for their prevention and correction. Materials and methods. An open pharmacoepidemiological prospective study was conducted based on the analysis of 230 medical records of patients with diagnosis of RA in the specialized department. Results of the study. Adverse events from the digestive system were developed in 52,2% patients taking disease-modifying antirheumatic drugs (DMARDs). The largest number of adverse events were registered for the methotrexate use. The average dose of methotrexate that led to adverse events was 15±7,1 mg per week. Correction of folate deficiency with the use of methotrexate was performed only in 84,4% of patients. NSAIDs-gastropathy was developed in 25,5% cases using of nonsteroidal anti-inflammatory drugs (NSAIDs)/ All patients taking NSAIDs and/or glucocorticosteroids received proton pump inhibitors. Conclusion. For the treatment of RA used DMARDs, NSAIDs, glucocorticosteroids. Adverse events are developing in most patients. Most often adverse events occured from the digestive system.

Ревматоидный артрит, фармакоэпидемиология, побочные реакции, базисные противовоспалительные препараты, глюкокортикостероиды, нестероидные противовоспалительные препараты, Rheumatoid arthritis, glucocorticosteroids, pharmacoepidemiology, adverse events, disease-modifying antirheumatic drugs, glucocorticosteroids, nonsteroidal anti-inflammatory drugs